These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20364382)

  • 1. Multi-modal treatment for metastatic renal cancer: the role of surgery.
    Russo P
    World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrectomy in metastatic renal cell carcinoma.
    Campbell SC; Flanigan RC; Clark JI
    Curr Treat Options Oncol; 2003 Oct; 4(5):363-72. PubMed ID: 12941196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.
    Russo P; O'Brien MF
    Urol Clin North Am; 2008 Nov; 35(4):679-86; viii. PubMed ID: 18992621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    Karam JA; Rini BI; Varella L; Garcia JA; Dreicer R; Choueiri TK; Jonasch E; Matin SF; Campbell SC; Wood CG; Tannir NM
    J Urol; 2011 Feb; 185(2):439-44. PubMed ID: 21167518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.
    Russo P; Synder M; Vickers A; Kondagunta V; Motzer R
    ScientificWorldJournal; 2007 Feb; 7():768-78. PubMed ID: 17619759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
    Powles T; Sarwar N; Stockdale A; Sarker SJ; Boleti E; Protheroe A; Jones R; Chowdhury S; Peters J; Oades G; O'Brien T; Sullivan M; Aitchison M; Beltran L; Worth D; Smith K; Michel C; Trevisan G; Harvey-Jones E; Wimalasingham A; Sahdev A; Ackerman C; Crabb S
    JAMA Oncol; 2016 Oct; 2(10):1303-1309. PubMed ID: 27254750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic renal cell carcinoma.
    Flanigan RC; Campbell SC; Clark JI; Picken MM
    Curr Treat Options Oncol; 2003 Oct; 4(5):385-90. PubMed ID: 12941198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
    Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.